Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 19/20 | 0.67 |
| ▸ | CSNK2A2 | P19784 | 12/20 | 0.67 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.67 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | METAP1 | P53582 | 1/20 | 0.50 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10134718 | 0.89 | CSNK2A1 (0.70) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL10134699 | 0.81 | CSNK2A1 (0.73) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL10134704 | 0.80 | CSNK2A1 (0.92) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL4972494 | 0.80 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL10132438 | 0.78 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL11932889 | 0.78 | CSNK2A1 (0.46) | CSNK2A1CSNK2A2CSNK2BJAK2METAP1 | |
| SCHEMBL4969705 | 0.74 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL10134703 | 0.74 | CSNK2A1 (0.67) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL10134690 | 0.74 | CSNK2A1 (0.73) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL30486996 | 0.73 | CSNK2A1 (0.80) | CSNK2A1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| WO-2009108912-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885 |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.